Skip to main content
Top
Published in: Clinical Rheumatology 1/2007

01-01-2007 | Original Article

Immunoglobulin E: a new diagnostic clue for Behçet’s disease?

IgE and Behçet’s disease

Authors: Ahmet Mesut Onat, Hakan Buyukhatipoglu, Mehmet Yilmaz, Ramazan Geyik, Ahmet Celik, Mehmet Akif Ozturk

Published in: Clinical Rheumatology | Issue 1/2007

Login to get access

Abstract

Behçet’s disease (BD) is a multisystemic inflammatory disorder of unknown etiology. Hyperimmunoglobulinemia has been demonstrated in BD; however, its clinical importance has not yet been discovered. In a few reports, an association between BD and plasma immunoglobulin E (IgE) has been noted. In this study, we had three objectives: (1) to investigate plasma levels of IgE and their association with levels of acute phase reactants, (2) to determine whether treatment has any effect upon IgE levels, and (3) to assess whether higher serum levels of IgE provide a clue for the diagnosis of BD. Fifty-two patients with BD, without any accompanying disease or condition that might lead to a rise in IgE, were compared with 51 age-matched healthy controls. Plasma levels of IgE, IgA, IgG, and IgM were analyzed by means of nephelometric analysis. Results showed that among the 52 patients, 23 (44%) had IgE levels that were higher than the upper limits of normal. IgE was not correlated with age, erythrocyte sedimentation rate, or C-reactive protein (p=0.59, p=0.57, and p=0.757, respectively). These relationships remained nonsignificant when multiple regression analysis was performed, with R 2 of 0.187 and p=0.057. Moreover, treatment of patients with elevated IgE did not produce any predictable IgE response. We conclude that Behçet’s patients commonly exhibit elevated plasma IgE levels. However, elevated IgE levels are not correlated with levels of acute phase reactants or disease activity. We suggest that IgE levels might be an independent diagnostic clue in Behçet’s patients.
Literature
2.
go back to reference Fessler BJ (2004) Behcet’s syndrome. In: Koopman WJ (ed) Arthritis and allied conditions. Williams & Wilkins, Baltimore, MD, pp 1835–1844 Fessler BJ (2004) Behcet’s syndrome. In: Koopman WJ (ed) Arthritis and allied conditions. Williams & Wilkins, Baltimore, MD, pp 1835–1844
3.
go back to reference Cengiz K (1990) Serum IgE concentrations in complete Behcet’s disease. J Clin Pathol 43:262PubMed Cengiz K (1990) Serum IgE concentrations in complete Behcet’s disease. J Clin Pathol 43:262PubMed
4.
go back to reference Scully C, Boyle P, Yap PL (1982) Immunoglobulins G, M, A, D and E in Behcet’s disease. Clin Chim Acta 120:237–242PubMedCrossRef Scully C, Boyle P, Yap PL (1982) Immunoglobulins G, M, A, D and E in Behcet’s disease. Clin Chim Acta 120:237–242PubMedCrossRef
5.
go back to reference Gul A (2001) Behcet’s Disease: an update on pathogenesis. Clin Exp Rheumatol 19:S6–S12PubMed Gul A (2001) Behcet’s Disease: an update on pathogenesis. Clin Exp Rheumatol 19:S6–S12PubMed
6.
go back to reference Fresko I (2002) Highlights of the 10th International Congress on Behcet’s Disease. Clin Exp Rheumatol 20:S59–S64PubMed Fresko I (2002) Highlights of the 10th International Congress on Behcet’s Disease. Clin Exp Rheumatol 20:S59–S64PubMed
Metadata
Title
Immunoglobulin E: a new diagnostic clue for Behçet’s disease?
IgE and Behçet’s disease
Authors
Ahmet Mesut Onat
Hakan Buyukhatipoglu
Mehmet Yilmaz
Ramazan Geyik
Ahmet Celik
Mehmet Akif Ozturk
Publication date
01-01-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 1/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-006-0335-x

Other articles of this Issue 1/2007

Clinical Rheumatology 1/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine